Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study

Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.

Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research